Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $26.8 million.

  • Eton Pharmaceuticals' Shares Outstanding (Weighted Average) rose 3.80% to $26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.8 million, marking a year-over-year increase of 3.80%. This contributed to the annual value of $25.8 million for FY2024, which is 0.69% up from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' Shares Outstanding (Weighted Average) is $26.8 million, which was down 0.00% from $26.8 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $26.8 million during Q1 2025, and registered a low of $24.4 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $26.0 million, with a median of $25.7 million in 2024.
  • Data for Eton Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 36.49% (in 2021) over the last 5 years.
  • Eton Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $24.6 million in 2021, then rose by 2.81% to $25.3 million in 2022, then increased by 1.43% to $25.7 million in 2023, then rose by 0.69% to $25.8 million in 2024, then climbed by 3.80% to $26.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $26.8 million for Q3 2025, versus $26.8 million for Q2 2025 and $26.8 million for Q1 2025.